Clinical trials
Phase 1 Purpura, Thrombocytopenic, Idiopathic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 9 |
| Completed | 4 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chongqing Peg-Bio Biopharm Co., Ltd. | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 1 |
| CytoCares Inc | 1 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 1 |
| Hutchison Medipharma Limited | 1 |
| Jian Zhu | 1 |
| Juventas Cell Therapy Ltd. | 1 |
| Peking Union Medical College Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Purpura, Thrombocytopenic, Idiopathic | 19 |
| Lupus Erythematosus, Systemic | 3 |
| Lupus Nephritis | 2 |
| Myositis | 2 |
| Anemia, Hemolytic, Autoimmune | 1 |
| Arthritis, Rheumatoid | 1 |
| Autoimmune Diseases | 1 |
| Recurrence | 1 |
| Scleroderma, Systemic | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.